Drug Profile
Research programme: cancer therapeutics - Boehringer Ingelheim/FORMA
Latest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; FORMA Therapeutics
- Class Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 09 Jan 2014 Early research is ongoing in USA